Inhibrx (INBX) said Monday its investigational treatment INBRX-106 combined with pembrolizumab achieved a higher objective response rate compared with pembrolizumab alone in a phase 2 trial in patients with metastatic or unresectable recurrent head and neck squamous cell carcinoma.
The company said an interim analysis of phase 2 data showed that the combination therapy generated a 44% confirmed objective response rate, compared with 21.4% from pembrolizumab monotherapy, and that majority of the responding patients achieved tumor reductions of over 50%, with three patients demonstrating a complete radiographic response.
The combination therapy showed a manageable safety profile, with no treatment-related fatalities, Inhibrx said.
The company said it plans to start a phase 3 study in Q3 and expects to publish progression-free survival metrics in Q4.
Shares of the company were up 1.3% in Monday trading.
Price: $136.11, Change: $+1.76, Percent Change: +1.31%